4 results on '"Osvaldo L. Cerda"'
Search Results
2. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
- Author
-
Carolina A. Isnardi, Osvaldo L. Cerda, Margarita Landi, Leonel Cruces, Emilce E. Schneeberger, Claudia Calle Montoro, María Agustina Alfaro, Brian M. Roldán, Andrea B. Gómez Vara, Pamela Giorgis, Roberto Alejandro Ezquer, María G. Crespo Rocha, Camila R. Reyes Gómez, Mária de los Ángeles Correa, Marcos G. Rosemffet, Virginia Carrizo Abarza, Santiago Catalan Pellet, Miguel Perandones, Cecilia Reimundes, Yesica Longueira, Gabriela Turk, María Florencia Quiroga, Natalia Laufer, Rosana Quintana, María Celina de la Vega, Nicolás Kreplak, Marina Pifano, Pablo Maid, Guillermo J. Pons-Estel, and Gustavo Citera
- Subjects
Vaccines ,COVID-19 Vaccines ,SARS-CoV-2 ,Immunology ,Vaccination ,Immunity ,COVID-19 ,Antibodies, Viral ,Arthritis, Rheumatoid ,Abatacept ,Rheumatology ,ChAdOx1 nCoV-19 ,Immunoglobulin G ,Immunology and Allergy ,Humans ,Rituximab ,BNT162 Vaccine - Abstract
ObjectiveThe aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses.MethodsPatients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose.ResultsA total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128;P= 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%,P= 0.03).ConclusionIn this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.
- Published
- 2022
3. Conceptos emergentes de tolerancia y autoinmunidad: Nuevos enfoques terapéuticos Tolerance and autoimmunity: Novel therapeutic approaches
- Author
-
Esteban Ciliberti, Leandro Carambia, Sebastián Cavallin, Osvaldo L. Cerda, Juan J. Poderoso, and Gabriel A. Rabinovich
- Subjects
lcsh:Immunologic diseases. Allergy ,Galectinas ,Enfermedades autoinmunes ,Autoimmune diseases ,Galectins ,lcsh:R ,lcsh:Medicine ,lcsh:RC109-216 ,Self tolerance ,lcsh:RC581-607 ,Tolerancia ,lcsh:Infectious and parasitic diseases - Abstract
La función primaria del sistema inmune es resguardar al individuo de los patógenos potencialmente dañinos que invaden el medio ambiente en el cual nos desarrollamos. Este cuenta con dos grandes ramas, la inmunidad innata y la adaptativa, ambas con la propiedad de diferenciar lo peligroso de aquello inofensivo. Estos procesos se hallan regulados por mecanismos homeostáticos que constituyen la tolerancia inmunológica, a los fines de limitar aquellos procesos prolongados y silenciar los potencialmente autoagresivos. Ante la falla de estos mecanismos de control, surgen las enfermedades autoinmunes. Avances en el conocimiento de la fisiopatología de estas entidades, han abierto un nuevo capítulo en el terreno de la inmunofarmacología. Su prometedor potencial actualmente nos ofrece novedosas herramientas terapéuticas para controlar y atenuar el daño causado por este tipo de respuestas. No obstante, debe continuarse la investigación en el campo de los agentes biológicos, ya que ninguno de ellos se encuentra libre de inconvenientes. Seguramente, futuros hallazgos se concretarán en futuros aciertos. Y los aciertos, en Medicina, equivalen a esperanza.The main function of the immune system is to protect the individual against potentially dangerous pathogens. It comprises innate and adaptive cellular and soluble components, both with the capacity to discriminate between harmful and harmless. These processes are regulated by homeostatic mechanisms that constitute the so-called immunological tolerance, which aims to limit the prolonged action of immune mediators and to silence the generation of potentially autoaggressive components. Failure to silence self-reactive T and B cells results in the generation of autoimmune disease. Recent advances in our knowledge of these pathological entities have opened a new chapter in the pharmacology of the immune system. Its promising potential currently offers new therapeutic agents to control and attenuate pathological tissue damage. Nevertheless, further research regarding these biologic agents is required, since they are not free from inconveniences. It is without question that upcoming findings in this field will instill hope into the quest for the "magic bullet".
- Published
- 2009
4. [Tolerance and autoimmunity. Novel therapeutic approaches]
- Author
-
Esteban, Ciliberti, Leandro, Carambia, Sebastian, Cavallin, Osvaldo L, Cerda, Juan J, Poderoso, and Gabriel A, Rabinovich
- Subjects
Immune Tolerance ,Humans ,Autoimmunity ,Communicable Diseases ,Autoimmune Diseases - Abstract
The main function of the immune system is to protect the individual against potentially dangerous pathogens. It comprises innate and adaptive cellular and soluble components, both with the capacity to discriminate between harmful and harmless. These processes are regulated by homeostatic mechanisms that constitute the so-called immunological tolerance, which aims to limit the prolonged action of immune mediators and to silence the generation of potentially autoaggressive components. Failure to silence self-reactive T and B cells results in the generation of autoimmune disease. Recent advances in our knowledge of these pathological entities have opened a new chapter in the pharmacology of the immune system. Its promising potential currently offers new therapeutic agents to control and attenuate pathological tissue damage. Nevertheless, further research regarding these biologic agents is required, since they are not free from inconveniences. It is without question that upcoming findings in this field will instill hope into the quest for the "magic bullet".
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.